Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Nontuberculous mycobacteria market to reach $4.6 billion in 7MM in 2033, forecasts GlobalData
Market expansion driven by novel pipeline drugs and rising diagnosed prevalence, but generic competition may limit uptake of…
Biocon Biologics expands insulin access in Malaysia
Public-private partnership with Malaysian government supports over 345,000 patients, strengthens local manufacturing and insulin…
Torrent Pharmaceuticals to acquire controlling stake in JB Pharma from KKR for ₹25,689 crore,…
Torrent to first acquire 46.39 per cent stake in JB Pharma and initiate open offer, aiming to integrate operations through merger…
Diagnosed prevalent cases of multiple sclerosis to increase by 0.19 per cent AGR in 7MM during…
GlobalData report highlights rising diagnosed prevalence of multiple sclerosis in the US, with middle-aged adults showing the…
Health Canada approves Biocon Biologics’ YESAFILI, first EYLEA biosimilar, for launch in July 2025
YESAFILI becomes Biocon Biologics’ tenth biosimilar to be commercialised globally, with Canada as the first launch market
Punjab Government and Ananya Birla Foundation launch DITSU to strengthen drug abuse response
Data Intelligence and Technical Support Unit to support evidence-based strategies, enforcement coordination, and community…
Kashmik Formulation plans 50 per cent production capacity expansion and targets ₹100 crore revenue…
Ahmedabad-based pharma company outlines investment and export strategies, automation upgrades, and long-term diversification into…
University of East Anglia and King’s College London release guidance for GPs managing patients using…
New recommendations aim to support primary care professionals as private use of GLP-1 medications such as Mounjaro and Ozempic…
Lupin launches Prucalopride Tablets in the US market post FDA approval
Lupin begins US sales of Prucalopride Tablets, bioequivalent to Takeda’s Motegrity, for chronic idiopathic constipation treatment
Sudeep Pharma files DRHP with SEBI for IPO to raise ₹95 Crore
The company files DRHP with SEBI to raise funds via IPO